Alessandro Datti

University of Toronto, Mount Sinai Hospital

Papers

3

Total Citations

128

H-Index

3

About

Alessandro Datti is a leading figure in high-throughput screening (HTS) and drug repurposing, with a career dedicated to translating chemical biology into therapeutic discovery. His research primarily targets infectious diseases and oncology, leveraging large-scale robotic screening to identify novel drug candidates. Datti’s most impactful work includes a pioneering 2010 study that screened over 4,000 compounds to identify synergistic inhibitors of *Plasmodium falciparum* heat shock protein 90, a critical target in malaria—a disease responsible for millions of deaths annually. This work, cited 90 times, underscores his contribution to combating antimalarial drug resistance. He also developed a solid-phase glycosyltransferase assay for HTS, a foundational tool in drug discovery research. In oncology, Datti co-authored a 2018 study testing agents against head and neck squamous cell carcinoma, revealing compounds with preferential activity in HPV-positive versus HPV-negative cell lines, offering new avenues for targeted therapy. With a career spanning assay development, chemical biology, and translational medicine, Datti’s work exemplifies the power of repurposing strategies and high-throughput technologies to address urgent medical needs.

Research Focus

Key Achievements

3
H-Index
3
Papers
128
Total Citations
43
Avg Citations/Paper
🏆 Most Cited Paper
A Repurposing Strategy Identifies Novel Synergistic Inhibitors of <i>Plasmodium falciparum</i> Heat Shock Protein 90
90 citations · 2010
📈 Most Prolific Year: 2010 (1 Papers)
🤝 Key Collaborators: 27
🏛 Institutions: University of Toronto, Mount Sinai Hospital

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago